Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m

Strides flagship facility in Bangalore receives USFDA inspection closure

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics

The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.

Strides Pharma Global receives AUD 94 mn for sale of Australia's operations

The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument

Strides receives USFDA approval for Potassium Chloride Oral Solution

The approval further strengthens the Potassium Chloride franchise for the company.

Strides receives USFDA approval for Naproxen Sodium OTC Softgel capsules

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma

Strides receives USFDA approval for Cyclosporine Softgel Capsules

Strides is the first Indian company to get approval for the product.

Strides receives USFDA approval for Ibuprofen OTC oral suspension

Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.

Strides receives USFDA approval for Ibuprofen Oral Suspension

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)

Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr

The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.